Chapitre I : problématique de la prise en charge pédiatrique du VIH en Afrique
Chapitre 7: Discussion générale
VII.5. Recommandations
VII.5.2. Pour la prise en charge pédiatrique
- Renforcer les politiques de sensibilisation pour accroître l’adhésion des populations et plus particulièrement des personnels de santé et des femmes enceintes au dépistage de l’infection à VIH.
- Renforcer la formation du personnel de santé dans le dépistage infantile précoce et la prise en charge des enfants infectés par le VIH.
- Renforcer le plateau technique des centres de prise en charge en matériel permettant le dépistage précoce de l’infection par le VIH chez l’enfant.
- Simplifier les circuits de prise en charge de l’infection par le VIH afin de limiter les perdus de vue.
- Mettre en place des stratégies actives pour dépister précocement les enfants exposés à l’infection à VIH dont les mères auraient été dépistées en prénatal, tout en préservant la confidentialité.
- Renforcer les liens entre les services de PTME et de VIH pédiatriques, en assurant une prise en charge globale des mères infectées par le VIH : accès au traitement antirétroviral, alimentation de l’enfant, conditions socio-économiques, etc.
- Impliquer le père dans la prise en charge de l’enfant et faciliter la communication au sein du couple autour de l’infection par le VIH.
106
Références
1. Gulliford M, Figueroa-Munoz J, Morgan M, Hughes D, Gibson B, Beech R, et al. What does 'access to health care' mean? J Health Serv Res Policy. 2002 Jul;7(3):186-8. 2. Dabis F, Desenclos J-C. Epidémiologie de terrain - Méthodes et applications. Eurotext JL, editor. London, United Kingdom. 2012.
3. Bourrillon A. Pédiatrie. 6e ed. Paris, France: Elsevier-Masson; 2011.
4. WHO. Lignes directrices unifiées sur l'utilisation des antirétroviraux pour le traitement et la prévention de l'infection à VIH - Recommendations pour un approche de santé publique
Genève, Suisse. 2013 [cited 2015 Feb 12]; Available from:
http://www.who.int/iris/bitstream/10665/101196/1/9789242505726_fre.pdf?ua=1.
5. Ancelle T. Statistique - Epidémiologie. 3e ed. Maloine, editor. Paris, France 2012. 6. Center for Disease Control and Prevention. First report of AIDS. MMWR June 1, 2001 / Vol. 50 / No. 21. Atlanta, USA. 2001 [cited 2015 Jan 22]; Available from:
http://www.cdc.gov/mmwr/PDF/wk/mm5021.pdf.
7. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science. 1983 May 20;220(4599):868-71.
8. UNAIDS. Facts and sheet 2014 [cited 2015 Jan 14]; Available from:
http://www.unaids.org/en/media/unaids/contentassets/documents/factsheet/2014/20140716_ FactSheet_en.pdf.
9. UNAIDS. Fact sheet - 2014 global statistics. 2015 [cited 2015 Nov 13]; Available from:
http://www.unaids.org/sites/default/files/media_asset/20150714_FS_MDG6_Report_en.pdf. 10. Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled
analysis. Lancet. 2004 Oct 2-8;364(9441):1236-43.
11. Harambat J, Fassinou P, Becquet R, Toure P, Rouet F, Dabis F, et al. 18-month occurrence of severe events among early diagnosed HIV-infected children before antiretroviral therapy in Abidjan, Cote d'Ivoire: a cohort study. BMC Public Health. 2008;8:169.
12. Obimbo EM, Mbori-Ngacha DA, Ochieng JO, Richardson BA, Otieno PA, Bosire R, et al. Predictors of early mortality in a cohort of human immunodeficiency virus type 1- infected african children. Pediatr Infect Dis J. 2004 Jun;23(6):536-43.
13. Chintu C, Dupont HL, Kaile T, Mahmoud M, Marani S, Baboo KS, et al. Human immunodeficiency virus-associated diarrhea and wasting in Zambia: selected risk factors and clinical associations. Am J Trop Med Hyg. 1998 Jul;59(1):38-41.
107
14. Rouet F, Sakarovitch C, Msellati P, Elenga N, Montcho C, Viho I, et al. Pediatric viral human immunodeficiency virus type 1 RNA levels, timing of infection, and disease progression in African HIV-1-infected children. Pediatrics. 2003 Oct;112(4):e289.
15. Walenda C, Kouakoussui A, Rouet F, Wemin L, Anaky MF, Msellati P. Morbidity in HIV-1-Infected children treated or not treated with highly active antiretroviral therapy (HAART), Abidjan, Cote d'Ivoire, 2000-04. J Trop Pediatr. 2009 Jun;55(3):170-6.
16. Becher H, Kynast-Wolf G, Sie A, Ndugwa R, Ramroth H, Kouyate B, et al. Patterns of malaria: cause-specific and all-cause mortality in a malaria-endemic area of west Africa. Am J Trop Med Hyg. 2008 Jan;78(1):106-13.
17. Dunn D. Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. Lancet. 2003 Nov 15;362(9396):1605-11.
18. Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008 Nov 20;359(21):2233-44.
19. WHO. Report to the WHO technical reference group, paediatric HIV/ART care guideline group meeting. Geneva, Switzerland 2008.
20. WHO. Antiretroviral therapy for HIV infection in infants and children: Towards universal access. Recommendations for a public health approach - 2010 revision. 2010; 206]. Available from: http://whqlibdoc.who.int/publications/2010/9789241599801_eng.pdf. 21. Penazzato M, Prendergast AJ, Muhe LM, Tindyebwa D, Abrams EJ. Optimization of antiretroviral therapy in HIV-infected children under 3 years of age: a systematic review. AIDS. 2014 Mar;28 Suppl 2:S137-46.
22. WHO. Consolidated guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection - Summary of key features and recommendations. Geneva, Switzerland. 2013 [cited 2015 Jan 20]; Available from:
http://www.who.int/iris/bitstream/10665/85322/1/WHO_HIV_2013.7_eng.pdf?ua=1. 23. WHO. Guideline on when to start antiretroviral therapy and pre-exposure prophylaxis for HIV. Geneva 2015 [cited 2015 Oct 11]; Available from:
http://apps.who.int/iris/bitstream/10665/186275/1/9789241509565_eng.pdf.
24. Sherr L, Cluver L, Tomlinson M, Coovadia H. Defeating AIDS but missing children. Lancet. 2015 Sep 12;386(9998):1035.
25. Chantry CJ, Cooper ER, Pelton SI, Zorilla C, Hillyer GV, Diaz C. Seroreversion in human immunodeficiency virus-exposed but uninfected infants. Pediatr Infect Dis J. 1995 May;14(5):382-7.
26. McIntosh K, FitzGerald G, Pitt J, Bremer JW, Hillyer GV, Landesman S, et al. A comparison of peripheral blood coculture versus 18- or 24-month serology in the diagnosis of human immunodeficiency virus infection in the offspring of infected mothers. Women and Infants Transmission Study. J Infect Dis. 1998 Aug;178(2):560-3.
108
27. Children born to women with HIV-1 infection: natural history and risk of transmission. European Collaborative Study. Lancet. 1991 Feb 2;337(8736):253-60. 28. Sutthent R, Gaudart N, Chokpaibulkit K, Tanliang N, Kanoksinsombath C, Chaisilwatana P. p24 Antigen detection assay modified with a booster step for diagnosis and monitoring of human immunodeficiency virus type 1 infection. J Clin Microbiol. 2003 Mar;41(3):1016-22.
29. Patton JC, Sherman GG, Coovadia AH, Stevens WS, Meyers TM. Ultrasensitive human immunodeficiency virus type 1 p24 antigen assay modified for use on dried whole- blood spots as a reliable, affordable test for infant diagnosis. Clin Vaccine Immunol. 2006 Jan;13(1):152-5.
30. De Baets AJ, Edidi BS, Kasali MJ, Beelaert G, Schrooten W, Litzroth A, et al. Pediatric human immunodeficiency virus screening in an African district hospital. Clin Diagn Lab Immunol. 2005 Jan;12(1):86-92.
31. Fischer A, Lejczak C, Lambert C, Servais J, Makombe N, Rusine J, et al. Simple DNA extraction method for dried blood spots and comparison of two PCR assays for
diagnosis of vertical human immunodeficiency virus type 1 transmission in Rwanda. J Clin Microbiol. 2004 Jan;42(1):16-20.
32. Dunn DT, Brandt CD, Krivine A, Cassol SA, Roques P, Borkowsky W, et al. The sensitivity of HIV-1 DNA polymerase chain reaction in the neonatal period and the relative contributions of intra-uterine and intra-partum transmission. AIDS. 1995 Sep;9(9):F7-11. 33. Desire N, Dehee A, Schneider V, Jacomet C, Goujon C, Girard PM, et al.
Quantification of human immunodeficiency virus type 1 proviral load by a TaqMan real- time PCR assay. J Clin Microbiol. 2001 Apr;39(4):1303-10.
34. Sherman GG, Stevens G, Jones SA, Horsfield P, Stevens WS. Dried blood spots improve access to HIV diagnosis and care for infants in low-resource settings. J Acquir Immune Defic Syndr. 2005 Apr 15;38(5):615-7.
35. Lambert JS, Harris DR, Stiehm ER, Moye J, Jr., Fowler MG, Meyer WA, 3rd, et al. Performance characteristics of HIV-1 culture and HIV-1 DNA and RNA amplification assays for early diagnosis of perinatal HIV-1 infection. J Acquir Immune Defic Syndr. 2003 Dec 15;34(5):512-9.
36. Nesheim S, Palumbo P, Sullivan K, Lee F, Vink P, Abrams E, et al. Quantitative RNA testing for diagnosis of HIV-infected infants. J Acquir Immune Defic Syndr. 2003 Feb 1;32(2):192-5.
37. Young NL, Shaffer N, Chaowanachan T, Chotpitayasunondh T, Vanparapar N, Mock PA, et al. Early diagnosis of HIV-1-infected infants in Thailand using RNA and DNA PCR assays sensitive to non-B subtypes. J Acquir Immune Defic Syndr. 2000 Aug 15;24(5):401-7.
38. Garrido C, Zahonero N, Corral A, Arredondo M, Soriano V, de Mendoza C. Correlation between human immunodeficiency virus type 1 (HIV-1) RNA measurements
109
obtained with dried blood spots and those obtained with plasma by use of Nuclisens EasyQ HIV-1 and Abbott RealTime HIV load tests. J Clin Microbiol. 2009 Apr;47(4):1031-6. 39. Sherman GG, Stevens G, Stevens WS. Affordable diagnosis of human
immunodeficiency virus infection in infants by p24 antigen detection. Pediatr Infect Dis J. 2004 Feb;23(2):173-6.
40. Zijenah LS, Tobaiwa O, Rusakaniko S, Nathoo KJ, Nhembe M, Matibe P, et al. Signal-boosted qualitative ultrasensitive p24 antigen assay for diagnosis of subtype C HIV- 1 infection in infants under the age of 2 years. J Acquir Immune Defic Syndr. 2005 Aug 1;39(4):391-4.
41. Ribas SG, Ondoa P, Schupbach J, van der Groen G, Fransen K. Performance of a quantitative human immunodeficiency virus type 1 p24 antigen assay on various HIV-1 subtypes for the follow-up of human immunodeficiency type 1 seropositive individuals. J Virol Methods. 2003 Oct;113(1):29-34.
42. Knuchel MC, Jullu B, Shah C, Tomasik Z, Stoeckle MP, Speck RF, et al. Adaptation of the ultrasensitive HIV-1 p24 antigen assay to dried blood spot testing. J Acquir Immune Defic Syndr. 2007 Mar 1;44(3):247-53.
43. WHO. Recommendations on the diagnosis of HIV infection in infants and children Geneva, Switzerland 2010 [cited 2015 Jan 20]; Available from:
http://www.ncbi.nlm.nih.gov/books/n/whohivch/pdf/.
44. WHO. Antiretroviral therapy for HIV infection in infants and children: Towards universal access. Recommendations for a public health approach - 2010 revision. 2010 [cited 2015 Jan 22]; Available from:
http://whqlibdoc.who.int/publications/2010/9789241599801_eng.pdf.
45. Rakusan TA, Parrott RH, Sever JL. Limitations in the laboratory diagnosis of vertically acquired HIV infection. J Acquir Immune Defic Syndr. 1991;4(2):116-21. 46. Yapo V, d'Aquin Toni T, Desmonde S, Amani-Bosse C, Oga M, Lenaud S, et al. Evaluation of dried blood spot diagnosis using HIV1-DNA and HIV1-RNA Biocentric assays in infants in Abidjan, Cote d'Ivoire. The Pedi-Test DBS ANRS 12183 Study. J Virol Methods. 2013 Nov;193(2):439-45.
47. UNICEF. Towards an AIDS-free generation Children and AIDS; Sixth Stocktaking Report, 2013. [Report] New York, USA,2013 [updated Nov 2013; cited 2014 Jul 08];
Available from: http://www.childrenandaids.org/files/str6_full_report_29-11-2013.pdf. 48. Wettstein C, Mugglin C, Egger M, Blaser N, Vizcaya LS, Estill J, et al. Missed opportunities to prevent mother-to-child-transmission: systematic review and meta-analysis. AIDS. 2012 Nov 28;26(18):2361-73.
49. Ndondoki C, Brou H, Timite-Konan M, Oga M, Amani-Bosse C, Menan H, et al. Universal HIV screening at postnatal points of care: which public health approach for early infant diagnosis in Cote d'Ivoire? PLoS One. 2013;8(8):e67996.
110
50. Leroy V, Brou H, Oga M, Yapo V, Bosse-Amani C, Dago-Akribi H, editors. Family acceptability of pediatric HIV counseling and testing offered routinely during postnatal care for children under 6 months of age, in 2008, Abidjan, Côte d’Ivoire. The Project PEDI-TEST ANRS 12165. International AIDS Conference; 2009 July 19-23; Cape Town, South Africa.
51. Braun M, Kabue MM, McCollum ED, Ahmed S, Kim M, Aertker L, et al.
Inadequate coordination of maternal and infant HIV services detrimentally affects early infant diagnosis outcomes in Lilongwe, Malawi. J Acquir Immune Defic Syndr. 2011 Apr 15;56(5):e122-8.
52. European Medecine Agency. Science Medicines Health - Kaletra - Lopinavir ritonavir. London, UK. 2009 [updated 2015 Jan 30; cited 2015 Feb 04]; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Product_Information/human/000368/WC500039043.pdf.
53. European Medicine Agency. Science Medicines Health - Ziagen - Abacavir. London, UK. 2009 [updated 2014 Jun 06; cited 2015 Feb 04]; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Product_Information/human/000252/WC500050343.pdf.
54. Ministère des affaires sociales, de la santé et des droits des femmes, Republique Française. Bases de données publique des médicaments - Résumé Caractéristiques du Produit - Retrovir [updated 2015 Jan 30; cited 2015 Feb 05]; Available from: http://base- donnees-
publique.medicaments.gouv.fr/affichageDoc.php?specid=60524598&typedoc=R#RcpDuree Conservation.
55. European Medecine Agency. Science Medicines Health - Sustiva - Efavirenz. London, UK2009 [updated 2015 01/26; cited 2015 Feb 05]; Available from:
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_- _Product_Information/human/000249/WC500058311.pdf.
56. European Medecine Agency. Science Medicines Health - Epivir - Lamivudine. London, UK2009 [updated 2014 Dec 05 cited 2015 Feb 04]; Available from:
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_- _Product_Information/human/000107/WC500027572.pdf.
57. Bouvenot G, Eschwège E. Le Médicament. Paris : Cité des Sciences et de l’Industrie Pocket-Sciences; 1994.
58. MORIN M. De la recherche à l’intervention sur l’observance thérapeutique : contributions et perspectives des sciences sociales. Dans : L'observance aux traitements contre le VIH/sida - Mesure, déterminants, évolution. ANRS, editor 2001.
59. Muller AD, Jaspan HB, Myer L, Hunter AL, Harling G, Bekker LG, et al. Standard measures are inadequate to monitor pediatric adherence in a resource-limited setting. AIDS Behav. 2011 Feb;15(2):422-31.
111
60. Vreeman RC, Wiehe SE, Pearce EC, Nyandiko WM. A systematic review of
pediatric adherence to antiretroviral therapy in low- and middle-income countries. Pediatr Infect Dis J. 2008 Aug;27(8):686-91.
61. Davies MA, Boulle A, Fakir T, Nuttall J, Eley B. Adherence to antiretroviral
therapy in young children in Cape Town, South Africa, measured by medication return and caregiver self-report: a prospective cohort study. BMC Pediatr. 2008;8:34.
62. Barro M, Some J, Foulongne V, Diasso Y, Zoure E, Hien H, et al. Short-term virological efficacy, immune reconstitution, tolerance, and adherence of once-daily dosing of didanosine, lamivudine, and efavirenz in HIV-1-infected African children: ANRS 12103 Burkiname. J Acquir Immune Defic Syndr. 2011 Jul 1;57 Suppl 1:S44-9.
63. Haberer JE, Cook A, Walker AS, Ngambi M, Ferrier A, Mulenga V, et al. Excellent adherence to antiretrovirals in HIV+ Zambian children is compromised by disrupted routine, HIV nondisclosure, and paradoxical income effects. PLoS ONE.
2011;6(4):e18505.
64. Navarro J, Perez M, Curran A, Burgos J, Feijoo M, Torrella A, et al. Impact of an Adherence Program to Antiretroviral Treatment on Virologic Response in a Cohort of Multitreated and Poorly Adherent HIV-Infected Patients in Spain. AIDS Patient Care STDS. 2014 Aug 11.
65. Martinez BL, Riordan FA. Novel strategies in the use of lopinavir/ritonavir for the treatment of HIV infection in children. HIV AIDS (Auckl). 2010;2:59-67.
66. Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, Sheiner L, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000 Mar 10;14(4):357-66.
67. Leroy V, Malateste K, Rabie H, Lumbiganon P, Ayaya S, Dicko F, et al. Outcomes of antiretroviral therapy in children in Asia and Africa: a comparative analysis of the IeDEA pediatric multiregional collaboration. J Acquir Immune Defic Syndr. 2013 Feb 1;62(2):208-19.
68. Arrivé E, Anaki MF, Wemin ML, Diabate B, Rouet F, Salamon R, et al. Assessment of adherence to highly active antiretroviral therapy in a cohort of African HIV-infected children in Abidjan, Cote d'Ivoire. J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):498- 500.
69. Fassinou P, Elenga N, Rouet F, Laguide R, Kouakoussui KA, Timite M, et al. Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, Cote d'Ivoire. AIDS. 2004 Sep 24;18(14):1905-13.
70. Jaspan HB, Berrisford AE, Boulle AM. Two-year outcomes of children on non- nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program. Pediatr Infect Dis J. 2008 Nov;27(11):993-8. 71. Marazzi MC, Germano P, Liotta G, Buonomo E, Guidotti G, Palombi L. Pediatric highly active antiretroviral therapy in Mozambique: an integrated model of care. Minerva Pediatr. 2006 Oct;58(5):483-90.
112
72. Rouet F, Fassinou P, Inwoley A, Anaky MF, Kouakoussui A, Rouzioux C, et al. Long-term survival and immuno-virological response of African HIV-1-infected children to highly active antiretroviral therapy regimens. AIDS. 2006 Nov 28;20(18):2315-9.
73. Wamalwa DC, Farquhar C, Obimbo EM, Selig S, Mbori-Ngacha DA, Richardson BA, et al. Early response to highly active antiretroviral therapy in HIV-1-infected Kenyan children. J Acquir Immune Defic Syndr. 2007 Jul 1;45(3):311-7.
74. Meyers TM, Yotebieng M, Kuhn L, Moultrie H. Antiretroviral therapy responses among children attending a large public clinic in Soweto, South Africa. Pediatr Infect Dis J. 2011 Nov;30(11):974-9.
75. Reddi A, Leeper SC, Grobler AC, Geddes R, France KH, Dorse GL, et al. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa. BMC Pediatr. 2007;7:13.
76. Ruel TD, Kakuru A, Ikilezi G, Mwangwa F, Dorsey G, Rosenthal PJ, et al. Virologic and immunologic outcomes of HIV-infected Ugandan children randomized to
lopinavir/ritonavir or nonnucleoside reverse transcriptase inhibitor therapy. J Acquir Immune Defic Syndr. 2014 Apr 15;65(5):535-41.
77. Ciaranello AL, Chang Y, Margulis AV, Bernstein A, Bassett IV, Losina E, et al. Effectiveness of pediatric antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. Clin Infect Dis. 2009 Dec 15;49(12):1915-27.
78. Cotton MF, Violari A, Otwombe K, Panchia R, Dobbels E, Rabie H, et al. Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trial. Lancet. 2013 Nov 9;382(9904):1555-63.
79. Jesson J, Koumakpai S, Diagne NR, Amorissani-Folquet M, Koueta F, Aka A, et al. Effect of Age at Antiretroviral Therapy Initiation on Catch-up Growth Within the First 24 Months Among HIV-infected Children in the IeDEA West African Pediatric Cohort. Pediatr Infect Dis J. 2015 Jul;34(7):e159-68.
80. Desmonde S, Dicko F, Koueta F, Eboua T, Balestre E, Amani-Bosse C, et al.
Association between age at antiretroviral therapy initiation and 24-month immune response in West-African HIV-infected children. AIDS. 2014 Jul 17;28(11):1645-55.
81. Violari A, Lindsey JC, Hughes MD, Mujuru HA, Barlow-Mosha L, Kamthunzi P, et al. Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. N Engl J Med. 2012 Jun 21;366(25):2380-9.
82. WHO. Countries - Burkina Faso - Statistics. 2015 [cited 2015 Mar 03]; Available from: http://www.who.int/countries/bfa/en/.
83. WHO. Pays - Côte d'Ivoire - Statistiques. 2015 [cited 2015 Mar 03]; Available from: http://www.who.int/countries/civ/fr/.
113
84. WHO. Global Health Observatory Data Repository - Burkina Faso statistics summary (2002 - present). 2014 [cited 2015 Jan 16]; Available from:
http://apps.who.int/gho/data/node.country.country-BFA.
85. WHO. Global Health Observatory Data Repository - Côte d'Ivoire - statistics summary (2002 - present). 2014 [cited 2015 Jan 16]; Available from:
http://apps.who.int/gho/data/node.country.country-CIV.
86. Ciaranello AL, Park JE, Ramirez-Avila L, Freedberg KA, Walensky RP, Leroy V. Early infant HIV-1 diagnosis programs in resource-limited settings: opportunities for improved outcomes and more cost-effective interventions. BMC Med. 2011;9:59. 87. O'Gorman DA, Nyirenda LJ, Theobald SJ. Prevention of mother-to-child
transmission of HIV infection: views and perceptions about swallowing nevirapine in rural Lilongwe, Malawi. BMC Public Health. 2010;10:354.
88. Ministère de la Santé Burkina Faso. Annuaire statistique 2011. Ouagadougou, Burkina Faso2012 [cited 2013 May 27]; Available from:
http://www.sante.gov.bf/phocadownload/Annuaire_statistique_2011.pdf.
89. Statistiques mondiales. Afrique de l'Ouest: carte. 2014 [cited 2015 Feb 16]; Available from: http://www.statistiques-mondiales.com/carte_afrique_ouest.htm. 90. Institut National de la Statistique et de la Démographie Burkina Faso. Les 13 régions du Burkina Faso. Ouagadougou, Burkina Faso 2013 [cited 2015 Feb 16]; Available from: http://www.insd.bf/n/images/cartes/carte_burkina.png.
91. Ministère de la Santé Burkina Faso. Annuaire statistique 2013. Ouagadougou, Burkina Faso2014 [cited 2015 Feb 17]; Available from:
http://www.sante.gov.bf/index.php/publications-statistiques/file/409-annuaire-statistique- 2013.
92. Institut National de la Statistique et de la Démographie Burkina Faso. La région du centre en chiffres. Ouagadougou, Burkina Faso. 2011 [cited 2014 Aug 04]; Available from:
http://www.insd.bf/n/contenu/statistiques_regions/regions_en_chiffres_en_2011/reg_chif_c _2011.pdf.
93. Ministère de la Santé du Burkina Faso. Annuaire statistique 2010. Ouagadougou, Burkina Faso. 2011 [cited 2013 Apr 23]; Available from:
http://www.sante.gov.bf/images/stories/pdf/annuaire_statistique_sante_2010.pdf.
94. Ministère de l'économie et des finances Burkina Faso. Enquête Démographique et de Santé et à indicateurs multiples (EDSBF-MICS IV) 2010. . Ouagadougou, Burkina Faso 2011 [cited 2013 Apr 22]; Available from:
www.measuredhs.com/pubs/pdf/PR9/PR9.pdf.
95. Ministère de la Santé, Comité Ministériel de Lutte contre le SIDA Burkina Faso. Normes et protocoles de prise en charge médicale des personnes vivant avec le VIH au Burkina Faso. 3ème ed. Ouagadougou, Burkina Faso 2008.
114
96. Nation online. Administrative map of Cote d'Ivoire (Ivory Coast). 2014 [cited 2015 Mar 03]; Available from: http://www.nationsonline.org/oneworld/map/cote-dIvoire-
administrative-map.htm.
97. WHO. Côte d’Ivoire Country Cooperation Strategy at a glance. 2014 [updated May 2014; cited 2015 Oct 24]; Available from:
http://www.who.int/entity/countryfocus/cooperation_strategy/ccsbrief_civ_en.pdf. 98. WHO. Côte d'Ivoire - Statistiques. [cited 2015 Oct 24]; Available from: http://www.who.int/countries/civ/fr/.
99. République de Côte d’ivoire, Ministère de la Santé et de la Lutte contre le Sida (MSLS), Programme national de prise en charge médicale des personnes vivant avec le VIH. Plan d’élimination de la Transmission Mère-Enfant du VIH de la Côte d’Ivoire 2012 – 2015. Abidjan 2012.
100. Institut National de la Statistique (INS) et ICF International. Enquête Démographique et de Santé et à Indicateurs Multiples de Côte d’Ivoire 2011-2012.
Calverton, Maryland, USA : INS et ICF International. 2012 [cited 2015 Nov 11]; Available from: http://dhsprogram.com/pubs/pdf/FR272/FR272.pdf.
101. Sedgh G, Henshaw S, Singh S, Ahman E, Shah IH. Induced abortion: estimated rates and trends worldwide. Lancet. 2007 Oct 13;370(9595):1338-45.
102. WHO. Operations Manual for Delivery of HIV Prevention, Care and Treatment at Primary Health Centres in High-Prevalence, Resource-Constrained Settings. Edition 1 ed. Geneva, Switzerland 2008.
103. Forthofer RN, Lee ES, Hernandez M. Biostatistics: A guide to Design, Analysis, and Discovery. Second ed: Elsevier; 2007.
104. Tchidjou HK, Maria Martino A, Goli LP, Diop Ly M, Zekeng L, Samba M, et al.